Evidence map›Paper›PMID 41136567›Full record

ReviewEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026

A breath of fresh air: an updated review of nebulised tranexamic acid for post-tonsillectomy haemorrhage.

Jehad Owais, Haneen Tanous, Ahmed Ameur Ali Benlahrech, Chrystelle Chemaly, Emaan Khaliq, Myriam Boueri

Abstract readReview
PubMed Publisher
In one paragraph

Review in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jehad Owais *Pinderfields General Hospital, Mid Yorkshire Teaching NHS Trust, Aberford Rd, Wakefield, WF1 4DG, UK. jehad.owais@nhs.net.ORCID http://orcid.org/0009-0007-7102-9846
Haneen Tanous *Princess Basma Teaching Hospital, Ministry of Health, Irbid, Jordan.ORCID http://orcid.org/0000-0001-6823-4506
Ahmed Ameur Ali BenlahrechFaculty of Medicine, Ammar Telidji University, Laghouat, Algeria.ORCID http://orcid.org/0009-0006-6681-9651
Chrystelle ChemalyFaculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
Emaan KhaliqSheikh Zayed Medical College, Rahimyar Khan, Pakistan.
Myriam BoueriDivision of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA.ORCID http://orcid.org/0000-0003-3054-5776

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePost-tonsillectomy haemorrhage (PTH) remains a daunting complication that continues to challenge otolaryngologic care, especially among paediatric and high-risk patients. Traditional interventions often involve invasive or pharmacological approaches. This review investigates the emerging role of nebulised tranexamic acid (TXA) as a non-invasive, effective alternative in managing PTH, focusing on its clinical utility, mechanism of action, and safety.

methodsA comprehensive review of the current literature was conducted, including retrospective cohort studies, case reports, and observational studies that assessed the efficacy and safety of nebulised TXA in treating PTH. Pharmacokinetic evidence and mechanisms of action were also evaluated.

resultsThe reviewed studies consistently report high success rates in controlling haemorrhage with nebulised TXA, frequently reducing or eliminating the need for surgical intervention. The treatment demonstrated a rapid onset of local action with minimal systemic absorption and a favourable safety profile, with few adverse events noted. Despite promising outcomes, a lack of standardised dosing protocols and large-scale randomised controlled trials remains.

conclusionDespite the lack of standardised protocols, current literature suggests a shift in clinical thinking, one where TXA might transition from a supporting role to a starring one in PTH management. However, further large-scale trials are essential to validate its efficacy, determine optimal dosing strategies, and establish long-term safety. In the meantime, nebulised TXA remains an intriguing, evidence-informed option in the clinician's toolkit, one that may soon redefine the standard of care for PTH management.

Indexed as

Antifibrinolytic AgentsPostoperative HemorrhageTonsillectomyTranexamic AcidAdministration, InhalationHumansNebulizers and VaporizersAntifibrinolytic AgentsTranexamic AcidNebulised tranexamic acidNon-invasive haemostasisPost-tonsillectomy haemorrhageTonsillar haemorrhageTonsillectomy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.